Tricida, Inc. (TCDA): Price and Financial Metrics

Tricida, Inc. (TCDA)

Today's Latest Price: $7.43 USD

0.40 (5.69%)

Updated Nov 24 4:00pm

Add TCDA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TCDA Stock Price Chart Interactive Chart >

Price chart for TCDA

TCDA Price/Volume Stats

Current price $7.43 52-week high $44.30
Prev. close $7.03 52-week low $3.74
Day low $7.03 Volume 878,400
Day high $7.47 Avg. volume 695,083
50-day MA $8.29 Dividend yield N/A
200-day MA $19.73 Market Cap 372.87M

Tricida, Inc. (TCDA) Company Bio

Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.

TCDA Latest News Stream

Event/Time News Detail
Loading, please wait...

TCDA Latest Social Stream

Loading social stream, please wait...

View Full TCDA Social Stream

Latest TCDA News From Around the Web

Below are the latest news stories about Tricida Inc that investors may wish to consider to help them evaluate TCDA as an investment opportunity.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tricida, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $TCDA #TCDA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tricida, Inc.

Business Wire | August 28, 2020

FDA rejects Tricida's veverimer for metabolic acidosis in CKD patients

Tricida ([[TCDA]] -14.5%) has received a Complete Response Letter ((CRL)) from the FDA regarding its marketing application seeking approval of veverimer (TRC101) for metabolic acidosis in patients with chronic kidney disease ((CKD)).The application was reviewed under the Accelerated Approval Program.The CRL cited the need of additional data beyond the TRCA-301 and...

Seeking Alpha | August 24, 2020

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q2 2020 Results - Earnings Call Transcript

Tricida, Inc. (TCDA) Q2 2020 Earnings Conference Call August 05, 2020, 04:30 PM ET Company Participants Jackie Cossmon - SVP-IR and Communications Gerrit Klaerner - Founder, CEO and President Geoff Parker - CFO Conference Call Participants Phil Nadeau - Cowen & Company Alan Carr - Needham Graig Suvannavejh - Goldman...

SA Transcripts on Seeking Alpha | August 8, 2020

Tricida to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on Wednesday, August 5, 2020

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2020 financial results after the close of market on Wednesday, August 5, 2020. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress. The call or webcast may be accessed as follows:

Yahoo | July 29, 2020

Tricida (TCDA) Plummets on Regulatory Update on Veverimer

Tricida (TCDA) tanks on FDA notification about the identification of deficiencies in its ongoing review of the NDA for pipeline candidate, veverimer (TRC101).

Yahoo | July 17, 2020

Read More 'TCDA' Stories Here

TCDA Price Returns

1-mo -10.37%
3-mo -28.49%
6-mo -72.34%
1-year -81.35%
3-year N/A
5-year N/A
YTD -80.31%
2019 60.05%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7443 seconds.